Immunogenicity and safety of a rabies-based highly pathogenic #influenza A virus #H5 #vaccine in #cattle

 

Abstract

The circulation of highly pathogenic H5 influenza A viruses in cattle, other mammals, and wildlife threatens animal and human health. To address this, we vaccinated heifer-calves with a deactivated rabies-virus-based H5 vaccine, which was well-tolerated and elicited neutralizing antibodies against both clade-1 and clade-2.3.4.4b H5N1 viruses, comparable to naturally H5-infected and convalescing cows. The immune responses to the vaccine platform were durable for at least 200 days and unaffected by preexisting RABV immunity.

Source: npj Vaccines, https://www.nature.com/articles/s41541-025-01238-2

____

Genetic #reassortment and diversification of #host specificity have driven evolutionary trajectories of #lineages of #panzootic #H5N1 #influenza

 

Abstract

Since 2021, subclade 2.3.4.4b A(H5N1) high pathogenicity avian influenza (HPAI) viruses have undergone changes in ecology and epidemiology, causing a panzootic of unprecedented scale in wild and domestic birds with spill-over infections and perceptible transmission in a range of mammalian species, raising concern over zoonotic potential. HPAI viruses readily exchange gene segments with low pathogenicity avian influenza viruses via reassortment, a mechanism that facilitates pronounced phenotypic change. Observations suggest changes in the seasonality and host range of panzootic viruses, however, data on the role of reassortment in determining such features are limited. Using phylodynamic approaches, we describe the emergence of the panzootic lineage and using a novel global genotype classification system we describe the subsequent emergence and global structuring of genotypes generated by reassortment. Focusing on evolutionary dynamics in Europe, we show reassortment has produced high fitness genotypes with enhanced capacity for transmission and further we show such advantages can be host-dependent, contrasting successful generalist genotypes with a specialist lineage (EA-2022-BB) adapted to birds of the order Charadriiformes. Experimental investigation of NS1-mediated shutoff indicates this Charadriiformes-specialist does not inhibit host cellular gene expression and hamper the defences of more typical hosts such as water- and land-fowl. We attribute this primarily to variation at position 127 of the NS1 protein. Our results emphasise that reassortment has driven phenotypic change, affected viral fitness, and caused diversification of host specificity and seasonality. Such factors should be considered in studies that seek to identify drivers of HPAI spread and map spillover risk. Additionally, relaxation of host specialisation, ecological diversification, and potential endemicity in atypical host populations present new reassortment opportunities that could result in further novel phenotypes.

Competing Interest Statement

The authors have declared no competing interest.

Funder Information Declared

Biotechnology and Biological Sciences Research Council, BB/X006204/1, BB/X006166/1, BB/Y007271/1, BB/Y007298/1, BB/V011286/1

BBSRC Institute Strategic Grant, BBS/E/RL/230002C, BBS/E/RL/230002D, BBS/E/PI/230002A, BBS/E/PI/230002B

Medical Research Council, MR/Y03368X/1

European Union, https://ror.org/019w4f821, 874735

Department for Environment Food and Rural Affairs, https://ror.org/00tnppw48, SE2223, SE2230, SV3400, SV3032, SV3006

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.08.20.670882v1

____

Circulating vaccine-derived #poliovirus type 1 [#cVDPV1] - #Israel (#WHO D.O.N., August 20 '25)

 

Situation at a glance

On 4 August 2025, Israel notified WHO of a circulating vaccine-derived poliovirus type 1 (cVDPV1) outbreak. 

Between February and July 2025, nine genetically linked virus isolates were found in environmental samples from seven sites, mainly in Jerusalem and the Central Region. 

No human cases of paralytic polio have been reported. 

Israel discontinued routine use of the bivalent oral polio vaccine in March 2025 but continues using inactivated polio vaccine (IPV) as part of the country’s routine immunization schedule. 

WHO and partners of the Global Polio Eradication Initiative are supporting national and subnational authorities. 

WHO assesses the risk of international spread of this cVDPV1 outbreak in Israel as low, due to strong overall immunity, surveillance, and response systems. 

However, the virus is circulating in under-vaccinated, vaccine-sceptic communities with ties to similar groups abroad, posing a potential risk for further spread.

Description of the situation

On 4 August 2025, WHO received an International Health Regulations notification from the IHR National Focal Point (NFP) for Israel reporting the declaration of a circulating vaccine-derived poliovirus type 1 (cVDPV1) outbreak in the country. 

Between February and July 2025, nine genetically related VDPV1 isolates were detected in environmental samples collected from seven sampling sites, four of which are geographically non-overlapping in the Jerusalem district and Central Region. 

Laboratory analyses and whole-genome sequencing (WGS) indicate that these viruses are genetically linked to each other and to multiple Sabin-like viruses isolated from environmental samples since October 2024. 

As of 8 August 2025, cVDPV1 has been detected only in environmental samples, with no paralytic cases reported at this stage. 

However current evidence supports classification of this event as an outbreak of cVDPV1 with sustained community transmission.

Prior to this outbreak a Sabin-like type 1 virus (SL1), related to SL1 viruses detected in environmental surveillance, was the cause of an acute flaccid paralysis (AFP) case in an unvaccinated 17-year-old male from Jerusalem that was reported on 23 December 2024 and classified as vaccine-associated paralytic poliomyelitis (VAPP). 

Israel discontinued routine use of the bivalent oral polio vaccine (bOPV) in March 2025 but continues to administer four doses of inactivated polio vaccine (IPV) as part of the routine immunization schedule up to 12 months of age. 

The WHO/UNICEF Estimates of National Immunization Coverage for three doses of IPV in 2024 was 98%. 

However, vaccination coverage in Jerusalem is notably lower and below WHO’s recommended coverage threshold, which is necessary to maintain sufficient population immunity and prevent poliovirus transmission.

Epidemiology

Polio is a highly infectious disease that largely affects children under five years of age, causing permanent paralysis (approximately 1 in 200 infections) or death (2-10% of those paralyzed).

The virus is transmitted from person-to-person, mainly through the fecal-oral route or, less frequently, by contaminated water or food. The virus multiplies in the intestine, from where it can invade the nervous system and cause paralysis. The incubation period is usually 7-10 days but can range from 4-35 days. Up to 90% of those infected are either asymptomatic or experience mild symptoms and the disease usually goes unrecognized.

Vaccine-derived poliovirus is a well-documented strain of poliovirus mutated from the strain originally contained in OPV. OPV contains a live, weakened form of poliovirus that replicates in the intestine for a limited period, thereby developing immunity by building up antibodies. On rare occasions, when replicating in the gastrointestinal tract, OPV strains can genetically change and may spread in communities that are not fully vaccinated against polio, especially in areas where there is poor hygiene, poor sanitation, or overcrowding. The lower the population's immunity, the longer vaccine-derived poliovirus survives and the more genetic changes it undergoes.

In very rare instances, the vaccine-derived virus can genetically change into a form that can cause paralysis as does the wild poliovirus – this is what is known as a vaccine-derived poliovirus (VDPV). The detection of VDPV in at least two different sources and at least two months apart, that are genetically linked, showing evidence of transmission in the community, is classified as cVDPV. Similar to wild poliovirus, cVDPVs can be of three types (1,2 or 3), the current outbreak in Israel is due to cVDPV1.

Public health response

Enhanced AFP and environmental surveillance to detect further transmission are ongoing. 

Under the Ministry of Health, a multi-disciplinary emergency response team (ERT) was established to support the control of outbreaks of cVDPV3 in 2022 followed by cVDPV2 in 2023 and this ERT continues to operate for this current cVDPV1 outbreak.

Investigations are ongoing to assess the scale of local circulation and the necessary responses where relevant.

Partners of the Global Polio Eradication Initiative, including the WHO European Regional Office, are supporting national and subnational authorities.

Targeted immunization campaigns with IPV have been ongoing since 2022, focusing on under-immunized communities. These campaigns are currently being intensified alongside measles vaccination efforts to maximize coverage. To enhance vaccine acceptance, the campaigns are supported by tailored, community-specific communication strategies.

Community- sensitive communication strategies are being developed with tailored messages to reduce the vaccine hesitancy and increase uptake.

WHO risk assessment

The international spread of poliovirus was declared a Public Health Emergency of International Concern (PHEIC) by the Director-General of the WHO on 5 May 2014, and most recently, the PHEIC declaration was extended on 28 July 2025. The outbreaks of cVDPV in Israel are covered by the original PHEIC declaration.

There is a high level of vaccination coverage and a robust surveillance system in Israel, however, the risk of further spread in the country is likely to be moderate as immunization gaps persist in known high-risk areas/population groups. 

Local health authorities are conducting field, epidemiological and virological investigations to better understand the situation and the likely risk of spread. Israel discontinued the use of bOPV in March 2025. The routine immunization schedule includes four doses of IPV-containing vaccine until the age of 12 months and a fifth dose during the second year of primary school. 

In 2024, a total of 11 cVDPV1 cases were reported, ten in the Democratic Republic of the Congo and one in Mozambique. Despite no cVDPV1 case detection for the past 10 months, continued low routine immunization and IPV coverage in several countries and associated immunity gap, indicate continued risk of cVDPV1 emergence.

WHO currently assesses the risk of international spread associated with this cVDPV1 detection as low due to high overall population immunity, robust poliovirus surveillance, and response capacity. 

However, the potential for spread exists, taking into account the fact that circulation is likely occurring in the vaccine-sceptic under vaccinated communities with known close ties to similar communities in other countries. An example of this being the 2022-2023 multi-country circulation of cVDPV2 in the UK, USA, Canada and Israel. 

WHO advice

The polio vaccine, given multiple times, can protect a child for life. WHO advises that every country should seek to achieve and maintain high levels of coverage with polio vaccine in support of the global commitment to eradicate polio. WHO recommends that all those who travel to or live in polio-affected areas should be fully vaccinated against polio in compliance with the national schedule. Population pockets with low immunity against polio should be prioritised for targeted interventions to boost immunity and reduce the risk of sustained transmission and spread.

It is important that all countries, in particular those with frequent travel and contact with polio-affected countries and areas, strengthen surveillance for AFP cases in order to rapidly detect any new virus importation and to facilitate a rapid response. Countries, territories, and areas should also maintain uniformly high routine immunization coverage at the district level to minimize the consequences of any new virus introduction.

As per the advice of the Emergency Committee convened under the International Health Regulations (2005), efforts to limit the international spread of poliovirus remain a PHEIC. 

Countries affected by poliovirus transmission are subject to Temporary Recommendations. 

To comply with the Temporary Recommendations issued under the PHEIC, any country infected by poliovirus should: 

-- declare the outbreak as a national public health emergency, 

-- consider vaccination of all international travellers, 

-- ensure such travellers are provided with an international certificate of vaccination, 

-- restrict at the point of departure the international travel of any resident lacking documentation of appropriate polio vaccination, 

-- intensify cross-border efforts to substantially increase vaccination coverage of travellers, and 

-- intensify efforts to increase routine immunization coverage. 

Any country subject to the temporary recommendation maintains the measures described above until the following criteria have been met:

-- At least six months have passed without new infections; and

-- There is documentation of the full application of high-quality eradication activities in all infected and high-risk areas. 

-- In the absence of such documentation, the measures should be maintained until the state meets the above assessment criteria for being no longer infected.

The latest epidemiological information on cVDPVs is updated on a weekly basis.  

WHO does not recommend any travel and/or trade restrictions to Israel based on the current information available for this event.

(...)

Source: World Health Organization, https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON578

____

#USA, #Missouri: DHSS confirms #death of #patient with rare brain #infection {#Naegleria Fowleri}

Aug. 20 Update:  

In response to several media inquiries following up on this case, DHSS regrets to confirm that the patient's death occurred on Aug. 19 in a St. Louis area hospital. We extend our deepest condolences to the loved ones of the patient. 

Source: Department of Health, https://content.govdelivery.com/accounts/MODHSS/bulletins/3eebf32

____

Novel #Henipavirus, Salt Gully Virus, Isolated from Pteropid #Bats, #Australia

 

Abstract

We describe isolation and characterization of a novel henipavirus, designated Salt Gully virus, from the urine of pteropid bats in Australia. We noted the virus to be most closely related to Angavokely virus, not reliant on ephrin receptors for cell entry, and of unknown risk for human disease.

Source: US Centers for Disease Control and Prevention, https://wwwnc.cdc.gov/eid/article/31/9/25-0470_article

____

Intensive #transmission in wild, migratory #birds drove rapid geographic #dissemination and repeated #spillovers of #H5N1 into agriculture in North #America

Abstract

Since late 2021, a panzootic of highly pathogenic H5N1 avian influenza virus has driven significant morbidity and mortality in wild birds, domestic poultry, and mammals. In North America, infections in novel avian and mammalian species suggest the potential for changing ecology and establishment of new animal reservoirs. Outbreaks among domestic birds have persisted despite aggressive culling, necessitating a re-examination of how these outbreaks were sparked and maintained. To recover how these viruses were introduced and disseminated in North America, we analyzed 1,818 Hemagglutinin (HA) gene sequences sampled from North American wild birds, domestic birds and mammals from November 2021-September 2023 using Bayesian phylodynamic approaches. Using HA, we infer that the North American panzootic was driven by ~8 independent introductions into North America via the Atlantic and Pacific Flyways, followed by rapid dissemination westward via wild, migratory birds. Transmission was primarily driven by Anseriformes, shorebirds, and Galliformes, while species such as songbirds, raptors, and owls mostly acted as dead-end hosts. Unlike the epizootic of 2015, outbreaks in domestic birds were driven by ~46-113 independent introductions from wild birds, with some onward transmission. Backyard birds were infected ~10 days earlier on average than birds in commercial poultry production settings, suggesting that they could act as early warning signals for transmission upticks in a given area. Our findings support wild birds as an emerging reservoir for HPAI transmission in North America and suggest continuous surveillance of wild Anseriformes and shorebirds as crucial for outbreak inference. Future prevention of agricultural outbreaks may require investment in strategies that reduce transmission at the wild bird/agriculture interface, and investigation of backyard birds as putative early warning signs.

Competing Interest Statement

The authors have declared no competing interest.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.12.16.628739v2

____

Diversity and #spillover #risk of swine acute diarrhea syndrome and related #coronaviruses in #China and Southeast #Asia

 

ABSTRACT

Bats are the reservoir hosts of emerging coronaviruses (CoVs) affecting human and livestock health. We assessed the diversity, evolution, and geographic distribution of two alphacoronaviruses (subgenus Rhinacovirus) with considerable potential for emergence: swine acute diarrhea syndrome coronavirus (SADS-CoV), which has caused large outbreaks in pigs in China and can infect primary human airway epithelial cells in vitro; and the related Rhinolophus bat coronavirus HKU2 (HKU2-CoV). Phylogenetic analyses of 523 rhinacovirus sequences from bats in China and Southeast Asia suggest these viruses should be reclassified into at least two distinct CoV species representing two well-supported monophyletic clades. Stronger phylogenetic clustering by sampling location than by host species suggests infrequent long-distance transmission of rhinacoviruses in southern China. Ancestral state reconstruction analysis indicates that R. sinicus/thomasi and R. affinis have played an important role in rhinacovirus evolution in southern China and that R. affinis is the likely reservoir host of SADS-CoV that spilled over into pigs. We used species distribution modeling of Rhinolophus spp. bat hosts of rhinacoviruses, combined with pig and human density data, to identify potential geographic rhinacovirus spillover risk in Southeast Asia. Areas of high pig density within suitable bat habitat exist primarily in southern China and northern Vietnam, and hotspots of the highest human density within suitable bat habitat are primarily along the southern coast of China, Java, and central Thailand. Targeted surveillance of pigs and people in these regions may facilitate the timely detection of bat CoV spillover events and mitigate the risk of future outbreaks.

IMPORTANCE

Bats are the reservoir or ancestral hosts of important emerging coronaviruses affecting people (e.g., SARS-CoV and SARS-CoV-2) and livestock (e.g., PEDV, SADS-CoV). Here, we analyzed 523 genetic sequences of SADS-CoV that caused large-scale die-offs of pigs in China, which is known to be able to infect human cells and related HKU2-CoVs. We used this information to identify the horseshoe bat Rhinolophus affinis as the likely spillover host for the outbreak in pigs, and identified the bat species within which these viruses evolved. We then modeled the distribution of these host species and their overlap with dense human and pig populations to identify the regions where surveillance programs can help identify spillover events and prevent future outbreaks.

Source: mBio, https://journals.asm.org/doi/full/10.1128/mbio.01197-24?af=R

____

Characterization of a #MERS-related #betacoronavirus in Danish brown long-eared #bats (Plecotus auritus)

 

Abstract

Background

Bats are recognized as natural reservoir hosts for numerous viruses and are believed to be the evolutionary origin of alpha- and beta-coronaviruses (CoVs), such as SARS-CoV, SARS-CoV-2, and possibly MERS-CoV. MERS-related beta-CoVs have been identified in bat species from Africa, America, Asia, and Europe. In this study, we describe the first detection and characterization of a MERS-related beta-CoV in Danish brown long-eared bats (Plecotus auritus).

Methods

Fecal samples collected through a national surveillance program were screened using pan-CoV RT-qPCRs. Positive samples underwent ORF1b sequencing, microarray analysis and Illumina MiSeq sequencing, followed by metagenomic assembly of full-length genomes. A global phylogenetic tree was used to determine placement within the Coronaviridae family and local maximum likelihood phylogenetic analysis clarified subgroup placement. The receptor-binding potential of the spike protein to human DPP4, ACE2, and bat ACE2 orthologs was assessed through phylogenetic analysis of the receptor-binding domain (RBD), alongside homology modeling and structural analysis.

Results

Three samples tested positive for CoVs. One sample from a Soprano pipistrelle (Pipistrellus pygmaeus) was identified as alpha-CoV by ORF1b sequencing. The remaining two samples, obtained from a colony of Plecotus auritus, were identified as beta-CoVs, and separate microarray results indicated the presence of a MERS-related CoV. Full genomes were successfully assembled using a metagenomic approach. Phylogenetic analysis placed them within the merbecoviruses, forming a distinct clade with viruses detected in Vespertilionidae bats from Western Europe and East Asia. Analysis of the RBD placed them within the HKU25 clade. Structural modeling suggested hydrogen bonding patterns between the RBD and human/bat ACE2 orthologs or human DPP4, similar to known in vitro complexes, indicating potential receptor binding.

Conclusion

This is the first report of MERS-related beta-CoVs in bats from Denmark. Phylogenetic analyses reveal that these novel viruses belong to the HKU25 clade, a clade with known ACE2 receptor preference. Experimental validation is needed to confirm the receptor-binding potential, as additional interactions at the RBD-receptor interface may differ from previously described bat-merbecoviruses. Continued surveillance is crucial to identify potential intermediate hosts and assess interspecies transmission risk, with focus on the spike protein, receptor specificity, and binding affinity.

Source: Virology Journal, https://virologyj.biomedcentral.com/articles/10.1186/s12985-025-02883-8

____

Higher #mortality in #ECMO patients during the #COVID19 #pandemic compared with #H1N1 #influenza: implications for future pandemics

 

Highlights

-- Higher Mortality in COVID-19 ECMO Patients: COVID-19 patients on ECMO had a significantly higher in-hospital mortality rate (52%) compared to H1N1 patients (6%) (p < 0.0001).

-- Increased Complications in COVID-19: COVID-19 patients had a higher incidence of complications, including:

• Secondary bloodstream infections (OR = 14.3; p = 0.003)

• Neurological complications

• Acute kidney injury requiring renal replacement therapy (RRT)

-- Longer ECMO Duration in COVID-19: COVID-19 patients required longer durations of ECMO support compared to H1N1 patients.

-- Age and Comorbidities Impact Mortality: Even after adjusting for age, BMI, gender, and ECMO duration, COVID-19 conferred a 16-fold higher risk of mortality compared to H1N1 (adjusted OR = 16.8).

Abstract

Background

Veno-venous Extracorporeal Membrane Oxygenation (V-V ECMO) in management of refractory respiratory failure due to viral respiratory infections has increased with recent pandemics.

Aims

The aim was to compare clinical characteristics and outcomes of patients requiring ECMO support during an evolving pandemic with COVID-19, with patients during the H1N1-influenza pandemic and subsequent seasonal epidemics, where adjunct therapy and vaccination was available.

Methods

Medical records of inpatients at an ECMO referral centre diagnosed with COVID-19 between March 2020 and October 2022 and requiring ECMO support were analysed. The clinical characteristics and outcomes of these patients were compared to data from patients with H1N1 influenza requiring ECMO between July 2009 and August 2017, treated at the same centre. The primary outcome of in-hospital mortality was analysed with a multivariate logistic regression model; categorical and continuous variables were compared using Fisher’s exact tests and two-sample T-tests, respectively.

Results

ECMO was used in 27 COVID-19 patients and 32 H1N1 influenza patients. Compared with H1N1 patients, COVID-19 patients were older (49.2±9.0 vs 42.3±11.1 years,p=0.01), and more likely to have comorbidities (59% vs 28%,p=0.02). Mortality was significantly higher for COVID-19 patients (52% vs 6%,p<0.0001), odds ratio 16.8 (95% CI: 1.27 - 221.39,p<0.05). Days on ECMO were longer in the COVID-19 group (20±13.3 vs 10±5.6 days,p<0.001). ECMO-related complication rates were similar between groups, apart from higher rates of secondary blood stream infections in COVID-19 patients (44% vs 6%,p<0.001).

Conclusion

Outcomes in patients with COVID-19 requiring ECMO support were worse than those requiring similar support during H1N1 seasons.

Source: Respiratory Medicine, https://www.resmedjournal.com/article/S0954-6111(25)00374-9/abstract

____

Modelling #transmission of #MERS #coronavirus in #camel populations and the potential impact of animal #vaccination

 

Abstract

Outbreaks of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans are driven by recurring zoonotic spillover from camels, leading to demand for camel vaccination. With two vaccine candidates shown to reduce infectiousness, there is a need to better understand transmission of MERS-CoV in camels and assess the potential impact of vaccination. To help address this, we used age-stratified seroprevalence data and a combination of modelling methodologies to estimate key epidemiological quantities including MERS-CoV transmissibility in camels and to estimate vaccine impact on infection incidence. Transmissibility was higher in West Asia (R0 interquartile range 7-14) compared to Africa (3-5) and South Asia (2-3), highlighting the need for setting-specific vaccination strategies. Modelling suggested that even if the vaccine only reduced infectiousness rather than susceptibility to infection, vaccinating calves could achieve large reductions in incidence in moderate and high transmission settings, and interrupt transmission in low transmission settings, provided coverage was high (70-90%).

Source: Nature Communications, https://www.nature.com/articles/s41467-025-62365-x

____

Estimates of #epidemiological #parameters for #H5N1 #influenza in #humans: a rapid review

 

Abstract

Background 

The ongoing H5N1 panzootic in mammals has amplified zoonotic pathways to facilitate human infection. Characterising key epidemiological parameters for H5N1 is critical should it become widespread. 

Aim 

To identify and estimate critical epidemiological parameters for H5N1 from past and current outbreaks, and to compare their characteristics with human influenza subtypes and the 2003 Netherlands H7N7 outbreak. 

Methods 

We searched PubMed, Embase, and Cochrane Library for systematic reviews reporting parameter estimates from primary data or meta-analyses. To address gaps, we searched PubMed and Google Scholar for studies of any design providing relevant estimates. We estimated the basic reproduction number for the recent outbreak in the United States (US) and the 2003 Netherlands H7N7 outbreak. In addition we estimated the serial interval for H5N1 using data from previous household clusters in Indonesia. We also applied a branching process model to simulate transmission chain size and duration to assess if simulated transmission patterns align with observed dynamics. 

Results 

From 46 articles, we identified H5N1s epidemiological profile as having lower transmissibility (R0 < 0.2) but higher severity compared to other human subtypes. Evidence suggests H5N1 has a longer incubation (~4 days vs ~2 days) and serial intervals (~6 days vs ~3 days) than human subtypes, impacting transmission dynamics. The epidemiology of the US H5 outbreak is similar to the 2003 Netherlands H7N7 outbreak. Key gaps remain regarding latent and infectious periods. 

Conclusions 

We characterised critical epidemiological parameters for H5N1 infection. The current US outbreak shows lower pathogenicity but similar transmissibility compared to prior outbreaks. Longer incubation and serial intervals may enhance contact tracing feasibility. These estimates offer a baseline for monitoring changes in H5N1 epidemiology.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the ESCAPE project (101095619), co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them. This work was co-funded by UK Research and Innovation (UKRI) under the UK governments Horizon Europe funding guarantee [grant number 10051037]. Epiverse is supported by data.org

Source: MedRxIV, https://www.medrxiv.org/content/10.1101/2024.12.11.24318702v4

____

Madonna and Child with Cherubs, Andrea Mantegna (1480 - 1490)

 

Public Domain.

Source: WikiArt, https://www.wikiart.org/en/andrea-mantegna/madonna-and-child-with-cherubs-1490

____

The #pathogenicity and multi-organ proteomic profiles of #Mpox virus #infection in SIVmac239-infected rhesus #macaques

 

Abstract

Mpox poses a heightened risk of severe disease and mortality among individuals with HIV, yet the molecular mechanisms and immunopathology underlying multi-organ damage caused by the mpox virus (MPXV), particularly in the context of HIV co-infection, remain poorly understood. Here, we observe increased MPXV replication, more extensive skin lesions, and impaired humoral and cellular immune responses in SIV-MPXV co-infected rhesus macaques compared to those infected with MPXV alone. Multi-organ proteomic and phosphoproteomic analyses reveals upregulation of proteins involved in immune and inflammatory pathways in skin lesions and across multiple organs, especially in immune-related tissues. Abnormal activation of DNA replication and cell cycle signaling pathways, which may contribute to enhanced viral replication, is evident in both MPXV and SIV-MPXV co-infected groups. CDK4/6 may present a potential therapeutic target to suppress MPXV replication. These comprehensive proteomic datasets offer valuable insights into the pathogenesis of MPXV in the context of SIV co-infection and support ongoing efforts to mitigate the impact of mpox.

Source: Nature Communications, https://www.nature.com/articles/s41467-025-62919-z

____

History of Mass Transportation: The TN ATR 124 Diesel-Electric Multiple Unit

 

Di Moliva - Opera propria, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=154882109

Source: Wikipedia, https://it.wikipedia.org/wiki/Autotreno_TN_ATR_125

____

History of Mass Transportation: The DB 111 Electric Locomotive

 

By Lars Steffens - Flickr: Baureihe 111, CC BY-SA 2.0, https://commons.wikimedia.org/w/index.php?curid=28019464

Source: Wikipedia, https://en.wikipedia.org/wiki/DB_Class_111

____

#Coronavirus Disease Research #References (by AMEDEO, August 16 '25)

 

Am J Obstet Gynecol

1. DALRYMPLE KV, Tydeman F, Bone JN, Poston L, et al
   The relationship between virtual antenatal care and pregnancy outcomes in a diverse UK inner-city population; A group-based trajectory modelling approach using routine health records.
   Am J Obstet Gynecol. 2025 Aug 11:S0002-9378(25)00538.
   PubMed         Abstract available
   
   

   
   Br J Anaesth

2. WATSON SL, Fowler AJ, Pearse RM, Abbott TEF, et al
   The financial cost of postoperative complications: a prospective cohort study with linked health systems data.
   Br J Anaesth. 2025 Aug 8:S0007-0912(25)00467-2. doi: 10.1016/j.bja.2025.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

3. TURJEMAN A, Drozdinsky G, Leibovici L
   The Impact of the COVID-19 Pandemic on Influenza Vaccination: A Multi-Year Interrupted Time Series Analysis.
   Int J Infect Dis. 2025 Aug 11:108015. doi: 10.1016/j.ijid.2025.108015.
   PubMed         Abstract available
   
   
4. CARAZO S, Ouakki M, Nicolakakis N, Falcone EL, et al
   Long COVID risk and severity after COVID-19 infections and reinfections: a retrospective cohort study among healthcare workers.
   Int J Infect Dis. 2025 Aug 7:108012. doi: 10.1016/j.ijid.2025.108012.
   PubMed         Abstract available
   
   

   
   J Infect

5. LI Z, Wang X, Chen S, Xiong W, et al
   Assessing Global Border Controls in Response to COVID-19 Pandemic Using Real-World Data and Target Trial Emulation.
   J Infect. 2025 Aug 12:106578. doi: 10.1016/j.jinf.2025.106578.
   PubMed         Abstract available
   
   
6. BUTLER CC, Hobbs FDR, Little P, Richards D, et al
   Removal notice to "Ivermectin and COVID-19" Journal of Infection 91 (2025) 106530.
   J Infect. 2025;91:106579.
   PubMed        
   
   
7. JANANI L, Munro APS, Wright A, Aley PK, et al
   Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial.
   J Infect. 2025 Aug 7:106576. doi: 10.1016/j.jinf.2025.106576.
   PubMed         Abstract available
   
   

   
   J Med Virol

8. WU Z, Jiang H, Zhou Y, Yang Y, et al
   A Clinical Investigation Into the Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Vaccination in Children With Acute Lymphoblastic Leukemia.
   J Med Virol. 2025;97:e70492.
   PubMed         Abstract available
   
   

   
   J Travel Med

9. PERLANT C, Klitting R, Colizza V, Gaythorpe KAM, et al
   A framework to assess the risk of Yellow Fever emergence.
   J Travel Med. 2025 Aug 6:taaf081. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

10. SUGIURA Y, Takahashi T, Ueno S, Amarbayasgalan S, et al
    Expression of spike and hemagglutinin-esterase proteins is necessary to recover infectious recombinant bovine coronavirus.
    J Virol. 2025 Aug 11:e0102725. doi: 10.1128/jvi.01027.
    PubMed         Abstract available
    
    
11. XIAO W, Xiong Y, Wang Y, Li T, et al
    Cathepsin L and transmembrane serine protease 11E mediate trypsin-independent entry of porcine deltacoronavirus into Huh7 cells.
    J Virol. 2025 Aug 11:e0105525. doi: 10.1128/jvi.01055.
    PubMed         Abstract available
    
    
12. KARIMI A, Lieber CM, Sakamoto K, Plemper RK, et al
    SARS-CoV-2 causes chronic lung inflammation and impaired respiratory capacity in aged Roborovski dwarf hamsters.
    J Virol. 2025 Aug 11:e0075525. doi: 10.1128/jvi.00755.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

13. LIU C, Rosen EA, Stohs EJ, Imlay H, et al
    Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship.
    Lancet Infect Dis. 2025 Aug 11:S1473-3099(25)00311.
    PubMed         Abstract available
    
    
14. RANSCOMBE P
    The quirky story behind New York's SARS-CoV-2 preparations.
    Lancet Infect Dis. 2025 Aug 8:S1473-3099(25)00505.
    PubMed        
    
    
15. NGUYEN-TRAN H, Park SW, Vogt MR, Permaul P, et al
    Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022-23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study.
    Lancet Infect Dis. 2025 Aug 6:S1473-3099(25)00349.
    PubMed         Abstract available
    
    

    
    Travel Med Infect Dis

16. NEUMANN JA, Zimmermann J, Frese M, Dirksen-Fischer M, et al
    Infectious diseases on passenger ships: Port preparedness and response - A narrative systematic review.
    Travel Med Infect Dis. 2025;67:102886.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, August 16 '25)

 

Antiviral Res

1. AL KRAD D, Stegmann KM, Dickmanns A, Kumar P, et al
   The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication.
   Antiviral Res. 2025 Jul 29:106247. doi: 10.1016/j.antiviral.2025.106247.
   PubMed         Abstract available
   
   
2. PATEL D, De R, Azadi N, Lee S, et al
   Discovery of broad-spectrum antivirals targeting viral proteases using in silico structural modeling and cellular analysis.
   Antiviral Res. 2025;241:106245.
   PubMed         Abstract available
   
   
3. LEBEDIN M, Petrovsky N, Tabynov K, Tabynov K, et al
   SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody.
   Antiviral Res. 2025;241:106235.
   PubMed         Abstract available
   
   

   
   Arch Virol

4. FERNANDEZ-ROJAS MA, Salazar AM, Ostrosky-Wegman P, Flisser A, et al
   A feedback loop between DNA damage, genomic instability, and cytoplasmic DNA sensing contributes to cytokine production in COVID-19.
   Arch Virol. 2025;170:192.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

5. ZHU H, Chen J, Dong X, Qin X, et al
   Influence of dihydrocaffeic acid and quinic acid on lung metabolism and function: Implications for dietary interventions.
   Biochem Biophys Res Commun. 2025;777:152274.
   PubMed         Abstract available
   
   
6. HODYNA D, Gryniukova A, Rogalsky S, Borysko P, et al
   Ionic liquids and lysosomotropic detergents as inhibitors of the SARS-CoV-2 main protease: QSAR modeling, synthesis and biological testing.
   Biochem Biophys Res Commun. 2025;777:152276.
   PubMed         Abstract available
   
   
7. ZHENG WH, Ni RZ, Ran XH, Mu D, et al
   Papain-like protease of SARS-CoV-2 inhibits dsRNA-induced type I interferon response partly by cleaving TBK1.
   Biochem Biophys Res Commun. 2025;777:152244.
   PubMed         Abstract available
   
   

   
   Cell

8. HUANG Y, Tan L, Liu Y, Zhao H, et al
   Response to: The mechanism for GTP-mediated RNA capping by the SARS-CoV-2 NiRAN domain remains unresolved.
   Cell. 2025;188:4462-4469.
   PubMed         Abstract available
   
   
9. SMALL GI, Darst SA, Campbell EA
   The mechanism for GTP-mediated RNA capping by the SARS-CoV-2 NiRAN domain remains unresolved.
   Cell. 2025;188:4456-4461.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

10. SMAGGE B, Labuschagne L, Pijpers J, van Roon A, et al
    Factors associated with lower COVID-19 vaccine uptake among populations with a migration background in the Netherlands.
    Epidemiol Infect. 2025;153:e87.
    PubMed         Abstract available
    
    

    
    J Infect Dis

11. ESPERSEN C, Johansen ND, Modin D, Janstrup KH, et al
    Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to frailty score: A post-hoc analysis of the DANFLU-1 randomized trial.
    J Infect Dis. 2025 Aug 13:jiaf420. doi: 10.1093.
    PubMed         Abstract available
    
    
12. WONG JY, Cheung JK, Iuliano AD, Wu P, et al
    Influenza-associated excess mortality associated with influenza B in Hong Kong, 2014-2023.
    J Infect Dis. 2025 Aug 6:jiaf414. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Virol

13. YAN Y, Xu J, Chen Z, Xu Y, et al
    Heat shock protein A1L restricts influenza A virus by ubiquitination of NA.
    J Virol. 2025 Aug 11:e0077125. doi: 10.1128/jvi.00771.
    PubMed         Abstract available
    
    
14. KELVIN AA, Baker PH, Ghosh S, Schultz-Cherry S, et al
    Influenza infection of the mammary gland.
    J Virol. 2025 Aug 12:e0194024. doi: 10.1128/jvi.01940.
    PubMed         Abstract available
    
    
15. DZIMIANSKI JV, Nagashima KA, Cruz JM, Sautto GA, et al
    Assessing the structural boundaries of broadly reactive antibody interactions with diverse H3 influenza hemagglutinin proteins.
    J Virol. 2025 Aug 14:e0045325. doi: 10.1128/jvi.00453.
    PubMed         Abstract available
    
    

    
    Pediatrics

16. ANTOON JW
    Influenza Antivirals: Do We Need More Evidence?
    Pediatrics. 2025 Aug 13:e2025071863. doi: 10.1542/peds.2025-071863.
    PubMed        
    
    
17. BASSETT HK, Rao S, Beck J, Brady PW, et al
    Clinician Preferences for Oseltamivir Use in Children With Influenza in the Outpatient Setting.
    Pediatrics. 2025 Aug 13:e2025071193. doi: 10.1542/peds.2025-071193.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

18. SCIANNA M, Gallotti R, Tizzoni M, Artime O, et al
    Comparing the effectiveness of ring and block-vaccination strategies on networks.
    PLoS Comput Biol. 2025;21:e1013274.
    PubMed         Abstract available
    
    
19. TIZZANI M, Gauvin L
    Socioeconomic determinants of protective behaviors and contact patterns in the post-COVID-19 pandemic era: A cross-sectional study in Italy.
    PLoS Comput Biol. 2025;21:e1013262.
    PubMed         Abstract available
    
    

    
    PLoS One

20. NAROUEI FH, Tang Z, Wang SI, Hashmi RH, et al
    Effects of germicidal far-UVC on ozone and particulate matter in a conference room.
    PLoS One. 2025;20:e0328224.
    PubMed         Abstract available
    
    
21. WYPLOSZ B, Grenier B, Roche N, Roubille F, et al
    Pneumococcal vaccination at 65 years and vaccination coverage in at-risk adults: A retrospective population-based study in France.
    PLoS One. 2025;20:e0329703.
    PubMed         Abstract available
    
    
22. SOEDER J, Preiser C, Wagner A, Neunhoffer AT, et al
    Pandemic preparedness in shaping psychosocial working conditions - insights for occupational safety and health from a longitudinal mixed-methods study during the COVID-19 pandemic at six company sites of one organization in Germany.
    PLoS One. 2025;20:e0328410.
    PubMed         Abstract available
    
    
23. BHAGAVATHI V, Ogum D, Agyabeng K, Coker-Appiah D, et al
    Unchanged but undecided: Reproductive intentions among Ghanaian women following COVID-19 lockdowns in two large metropolises in Ghana.
    PLoS One. 2025;20:e0328298.
    PubMed         Abstract available
    
    
24. TOUZET H, Privault S, Ward JK
    The role of professional socialisation in confidence in vaccines and vaccination decision-makers: Insights from a large multi-wave survey in France.
    PLoS One. 2025;20:e0328548.
    PubMed         Abstract available
    
    
25. RASMUSSEN MGB, Just-Ostergaard E, Stidsen JV, Willaing I, et al
    What is the impact of structural changes in society on diabetes self-management and trajectories of HbA1c? A cohort study before, during and after the COVID-19 pandemic in people with diabetes treated at outpatient clinics.
    PLoS One. 2025;20:e0329394.
    PubMed         Abstract available
    
    
26. ROY S, Biswas P, Ghosh P
    Advancing infection profiling under data uncertainty through contagion potential.
    PLoS One. 2025;20:e0329828.
    PubMed         Abstract available
    
    
27. MO J, Ferreri LM, Geiger G, Perez DR, et al
    Passage of human-origin influenza A virus in swine tracheal epithelial cells selects for adaptive mutations in the hemagglutinin gene.
    PLoS One. 2025;20:e0327096.
    PubMed         Abstract available
    
    
28. PRASERT K, Praphasiri P, Ditsungnoen D, Srichaijaroonpong S, et al
    Perceptions of influenza and SARS-CoV-2 vaccination among health care personnel in Thailand, 2024.
    PLoS One. 2025;20:e0329473.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

29. XU Y, Anirudhan V, Gaisina IN, Du H, et al
    Mechanistic insights into the small-molecule inhibition of influenza A virus entry.
    Proc Natl Acad Sci U S A. 2025;122:e2503899122.
    PubMed         Abstract available
    
    

    
    Vaccine

30. ASHRAF M, Stein AN, Youhanna J, Rockman S, et al
    The impact of egg adaptation and immune imprinting on influenza vaccine effectiveness.
    Vaccine. 2025;62:127393.
    PubMed         Abstract available
    
    

    
    Virology

31. CHERNYSHOVA AI, Zhirnov OP
    Influenza A virions with uncleaved hemagglutinin HA0 are more resistant to thermal inactivation than those with cleaved HA1/2: Research and applied significance.
    Virology. 2025 Jul 26:110644. doi: 10.1016/j.virol.2025.110644.
    PubMed        
    

#USA, #Wastewater #Data for Avian #Influenza #H5 (CDC, August 15 ' 25)

 

{Summary}

Time Period: August 03, 2025 - August 09, 2025

-- H5 Detection: 2 sites (0.5%)

-- No Detection: 425 sites (99.5%)

-- No samples in last week: 33 sites

(...)

Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/nwss/rv/wwd-h5.html

____

A clade 2.3.4.4b #H5N1 virus #vaccine that elicits cross-protective #antibodies against conserved domains of H5 and N1 glycoproteins

Abstract

The continuous evolution and widespread dissemination of highly pathogenic avian influenza (HPAI) H5N1 viruses, particularly clade 2.3.4.4b, pose critical challenges to global pandemic preparedness. In this study, we assessed a low-dose inactivated split virus vaccine derived from clade 2.3.4.4b H5N1, formulated with an Alum/CpG adjuvant, using a preclinical mouse model. This vaccine induced potent humoral and cellular immune responses, generating high titers of cross-reactive antibodies targeting both hemagglutinin (HA) and neuraminidase (NA) glycoproteins across homologous and heterologous H5 clades. The Alum/CpG adjuvant enabled significant antigen dose-sparing while promoting a balanced Th1/Th2 immune profile. Functional analyses demonstrated strong virus neutralization, neuraminidase inhibition, and potent antibody-dependent cellular cytotoxicity activity. Additionally, the vaccine elicited robust antigen-specific CD4+ and CD8+ T cell responses and effectively controlled viral replication in the lungs, accompanied by reduced lung inflammation. Importantly, vaccinated mice were fully protected against lethal challenges with both the homologous clade 2.3.4.4b and heterologous clade 1 H5N1 viruses, despite low hemagglutination inhibition titers. Electron microscopy polyclonal epitope mapping revealed serum antibodies targeting multiple epitopes on homologous HA and NA, with some cross-reacting to conserved epitopes on heterologous proteins, underscoring broad immune recognition. Collectively, these results highlight the potential of this vaccine candidate to provide broad, multifunctional, and durable immunity against both current and emerging H5N1 threats, supporting its further development for pandemic preparedness.

Competing Interest Statement

The Icahn School of Medicine at Mount Sinai has filed patent applications regarding influenza virus vaccines on which E.P.M. and F.K. are listed as inventors. F.K. has consulted for Merck, GSK, Gritstone, Sanofi, Curevac, Seqirus and Pfizer and is currently consulting for 3rd Rock Ventures and Avimex. The laboratory of F.K. is also collaborating with Dynavax on influenza vaccine development and with VIR on influenza virus therapeutics. A.B.W. has received royalty payments for the licensure of a prefusion coronavirus spike stabilization technology for which he is a co-inventor. A.B.W. and J.H. are currently consulting for Third Rock Ventures and Merida Biosciences. The laboratory of A.B.W. received unrelated sponsored research agreements from Third Rock Ventures during the conduct of the study. The authors declare that they have no other competing interests.

Funder Information Declared

NIAID, 75N93019C00051

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.08.14.670375v1

____

Detection of #antibodies specific to #H5 avian #influenza virus in a #sheep in #Norway, June 2024 ...

 

Abstract

A 2023 outbreak of highly pathogenic avian influenza in seabirds in Norway caused substantial environmental contamination of grazing areas frequented by local sheep. Eleven months later, 220 sheep were tested for antibodies to type A influenza and H5 subtype using ELISA, haemagglutination inhibition, and microneutralisation assays. One ewe (0.5%) tested positive by all methods, consistent with prior spillover infection. This underscores the importance of restricting livestock access to outbreak areas to mitigate cross-species transmission and zoonotic risk.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.08.14.670265v1

____